• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Generic Injectables Companies

    ID: MRFR/HC/6043-HCR
    100 Pages
    Rahul Gotadki
    October 2025

    Generic injectables refer to generic versions of injectable drugs, which are pharmaceutical products administered through injection. These drugs are often used in hospitals, clinics, and other healthcare settings for various medical conditions. Generic injectables are typically produced after the expiration of the patent protection of the original branded injectable drugs.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Generic Injectables Market Research Report – Global Forecast till 2035 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Generic Injectables Market

    Generic Injectables Key CompaniesLatest Generic Injectables Companies Update

    June 2023: Endo International plc has recently declared that its Par Sterile Products company has commenced the distribution of posaconazole injection (18 mg/mL), which is the initial generic iteration of Merck's Noxafil® in the United States. This action follows the conclusive acceptance of its Abbreviated New Drug Application by the U.S. Food and Drug Administration. The initial generic iteration of Noxafil® injection fulfills this objective, while enhancing our assortment of products and reinforcing our standing as a dependable and reputable provider. The use of posaconazole injection is recommended for the purpose of prophylaxis against invasive Aspergillus and Candida infections in individuals who are at a heightened risk of developing such infections due to severe immunocompromise. This includes patients who have undergone hematopoietic stem cell transplantation (HSCT) and are experiencing graft-versus-host disease (GVHD), as well as those with hematologic malignancies characterized by prolonged neutropenia resulting from chemotherapy.


    May 2022: Sandoz made an announcement on the availability of a generic version of Treprostinil Injection for the treatment of patients with pulmonary arterial hypertension (PAH) in the United States. This generic medication is now also accessible for subcutaneous administration. The Sandoz Treprostinil Injection is the initial fully-substitutable generic alternative to Remodulin® (treprostinil) Injection, a medication marketed by United Therapeutics Corporation. The specialized pharmacy that distributes the brand name medication now offers both intravenous and subcutaneous administration options for Sandoz generic Treprostinil Injection. This has been made possible through a partnership arrangement with Liquidia Corporation (LQDA), which has facilitated the commercialization process.


    List of Generic Injectables Key companies in the market

    • Novartis AG (Sandoz International GmbH)

    • Baxter

    • Fresenius SE & Co. KGaA

    • Mylan N.V.

    • Teva Pharmaceutical Industries Ltd.

    • Hikma Pharmaceuticals plc

    • Sanofi

    • Biocon

    • Reddy’s Laboratories

    • Aurobindo Pharma

    • Zydus Cadila

    • GlaxoSmithKline plc

    • AstraZeneca plc.